194 related articles for article (PubMed ID: 19790013)
21. Novel vaccines: bridging research, development and production - CHI's Inaugural Conference.
Ulmer JB
IDrugs; 2006 Oct; 9(10):696-8. PubMed ID: 17016775
[No Abstract] [Full Text] [Related]
22. Drug Development for Neurodegenerative Diseases--Second Annual marcus evans Conference. Advances in drug development for NDD and expediting discovery through novel compounds and sound clinical trials.
Morimoto B
IDrugs; 2010 Jul; 13(7):440-3. PubMed ID: 20582866
[TBL] [Abstract][Full Text] [Related]
23. CHI's Fourth Annual Drug Discovery Chemistry Conference. Kinase inhibitor chemistry: charting the chemical space. 7-8 April 2009, San Diego, CA, USA.
Seneci P
IDrugs; 2009 Jun; 12(6):358-62. PubMed ID: 19517315
[No Abstract] [Full Text] [Related]
24. American Chemical Society--238th National Meeting & Exposition. Developments in medicinal chemistry: part 2. 16-20 August 2009, Washington DC, USA.
Gater D; Macauley D
IDrugs; 2009 Oct; 12(10):608-11. PubMed ID: 19790005
[TBL] [Abstract][Full Text] [Related]
25. Vaccine provision: Delivering sustained & widespread use.
Preiss S; Garçon N; Cunningham AL; Strugnell R; Friedland LR
Vaccine; 2016 Dec; 34(52):6665-6671. PubMed ID: 27884478
[TBL] [Abstract][Full Text] [Related]
26. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
[TBL] [Abstract][Full Text] [Related]
27. Allergy vaccines: dreams and reality.
Crameri R
Expert Rev Vaccines; 2007 Dec; 6(6):991-9. PubMed ID: 18377361
[TBL] [Abstract][Full Text] [Related]
28. Biological Therapeutics Research and Development--GTCbio's Fifth Annual Conference. October 20-22, 2010, San Francisco, CA, USA.
Garren H
IDrugs; 2010 Dec; 13(12):840-2. PubMed ID: 21154139
[TBL] [Abstract][Full Text] [Related]
29. Target Discovery--Select Biosciences' World Congress. 4-5 August 2009, San Francisco, CA, USA.
Fernández A
IDrugs; 2009 Oct; 12(10):620-2. PubMed ID: 19790009
[TBL] [Abstract][Full Text] [Related]
30. Association for Research in Vision and Ophthalmology (ARVO)--2010 Annual Meeting. For Sight: The Future of Eye and Vision Research--part 2.
Hookes L
IDrugs; 2010 Jul; 13(7):430-2. PubMed ID: 20582863
[TBL] [Abstract][Full Text] [Related]
31. Summary and Recommendations from the National Institute of Allergy and Infectious Diseases (NIAID) Workshop "Gonorrhea Vaccines: the Way Forward".
Wetzler LM; Feavers IM; Gray-Owen SD; Jerse AE; Rice PA; Deal CD
Clin Vaccine Immunol; 2016 Aug; 23(8):656-63. PubMed ID: 27335384
[TBL] [Abstract][Full Text] [Related]
32. Current status and future prospects for the development of substance abuse vaccines.
Heekin RD; Shorter D; Kosten TR
Expert Rev Vaccines; 2017 Nov; 16(11):1067-1077. PubMed ID: 28918668
[TBL] [Abstract][Full Text] [Related]
33. Rational approach to selection and clinical development of TB vaccine candidates.
Barker L; Hessel L; Walker B
Tuberculosis (Edinb); 2012 Mar; 92 Suppl 1():S25-9. PubMed ID: 22441156
[TBL] [Abstract][Full Text] [Related]
34. American Chemical Society--238th National Meeting & Exposition. Novel small molecule therapeutics. 16-20 August 2009, Washington DC, USA.
Rotella DP
IDrugs; 2009 Oct; 12(10):612-3. PubMed ID: 19790006
[TBL] [Abstract][Full Text] [Related]
35. Vaccine clinical trials--a statistical primer.
Mehrotra DV
J Biopharm Stat; 2006; 16(4):403-14. PubMed ID: 16892903
[TBL] [Abstract][Full Text] [Related]
36. Bringing DNA vaccines closer to commercial use.
Carvalho JA; Prazeres DM; Monteiro GA
IDrugs; 2009 Oct; 12(10):642-7. PubMed ID: 19790015
[TBL] [Abstract][Full Text] [Related]
37. Vaccine adjuvant formulation: a relatively neglected field that is crucial to vaccine success.
Davies G
Expert Rev Vaccines; 2008 Apr; 7(3):287-91. PubMed ID: 18393597
[TBL] [Abstract][Full Text] [Related]
38. The golden era of vaccine adjuvants.
Cabrera O; Cuello M; Lastre M; Romeu B; Balboa J; Zayas C; Pérez O
Expert Rev Vaccines; 2011 Jul; 10(7):1007-9. PubMed ID: 21806395
[TBL] [Abstract][Full Text] [Related]
39. Current developments and prospects on human metapneumovirus vaccines.
Márquez-Escobar VA
Expert Rev Vaccines; 2017 May; 16(5):419-431. PubMed ID: 28116910
[TBL] [Abstract][Full Text] [Related]
40. Technology evaluation: NeuroVax, Immune Response Corp.
Darlington CL
Curr Opin Mol Ther; 2005 Dec; 7(6):598-603. PubMed ID: 16370383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
